The Diagnosable Value Of Serum COX-2 And ANXA1 In Breast Cancer

Objective:The serum concentration of COX-2 and ANXA1 were detected by enzyme linked immunosorbent assay in the patients of breast cancer in Guangxi.To study the value of combined assay of the two tumour markers in diagnosis of breast cancer, investigate their relationships with clinical and pathological characteristiecs.The immunohistochemistry method was used to detect the expressions of COX-2 and ANXAl in breast cancer, to investigate the relationship between serum concentration and tissues expression of the two makers.Methods:49 cases with breast cancer were studied,23 cases with benign breast diseases and 20 cases healthy people were randomly selected as control, The serum concentration of COX-2 and ANXA1 were detected by enzyme linked immunosorbent assay in these three groups.Besides,49 cases of breast cancer,23 cases of breast benign lesion tissues and 20 cases of breast normal tissues were selected in the same patients, the immunohistochemistry method was used to detect the expressions of COX-2 and ANXA1 in these tissues.Statistical analysis was performed by using spss 16.0χ2 test,LSD-t test and pearson correlations.Results:(1)The serum concentration of COX-2 in breast cancer group, benign lesion group and normal control are 52.419±9.755 ng/ml,21.404±8.748 ng/ml,14.498±7.591 ng/ml resectively; the serum concentration of ANXAl in three groups are 0.579±0.173 ng/ml,1.323±20.319 ng/ml,2.083±0.173 ng/ml respectively; The concentration of COX-2 in breast cancer group were higher than those innon-cancer group, The concentration of ANXA1 in breast cancer group were lower than those innon-cancer group,there were significant differences in the concentration of COX-2 and ANXA1(P<0.05). (2)The sensitivity rates of COX-2 and ANXA1 in breast cancer were 81.6%,89.8% respectively, the specific rates were 90.7%,76.75% respectively.In combined assay, the sensitivity rate was 95.9%, the secificity rate was 74.4%.(3) The concentration of two tumour markers in breast cancer group were negativity correlation.(4) In breast cancer group, high serum levels of COX-2 were significantly associated with stageⅢ,Ⅳ, lymph node involvement, negativity of both estrogen and progesterone receptors, positive of p53;low serum ANXA1 levels were significantly associated with big size, stageⅢ,Ⅳ, lymph node involvement, positive of p53,pl6 and HER-2; and there were statistical significance (p<0.05); (5)The expressions of COX-2 in breast cancer tissues were higher than it in breast benign lesion tissues and breast normal tissues, but the expressions of ANXA1 in breast cancer tissues were lower than it in breast benign lesion tissues and breast normal tissues, and there were statistical significance (p<0.05).There were positive correlation between the serum concentration and the expressions in breast cancer tissues of the two tumour markers.Conclusion:(1) The serum expression of COX-2 and ANXA1 in breast cancer clue to they can be used as tumor marker for diagnosis of breast cancer. (2) The serum expression of COX-2 and ANXA1 have value in diagnosis of breast cancer.In combined assay of COX-2 and ANXA1,the sensitivity rate was 95.9%, which showed good value in the diagnosis of breast cancer.(3) Serum concentration of COX-2 significantly correlates with clinic stage,lymph nodes metastasis,ER/PR,p53,and ANXA1 correlates with size clinic stage,lymph nodes metastasis,p53,p16,HER-2.It indicating the two markers are probably useful in evaluation and prognosis prediction of breast cancer. (4) There were positive correlation between the serum concentration and the expressions in breast cancer tissues of the two tumour markers.it showed that monitoring the serum concentration of the two markers is helpful to know their expressions in tissues.